Evidence map›Paper›PMID 38819667›Full record

ArticlePediatric surgery international2024

Evaluation of surgical strategies and long-term outcomes in pediatric hepatocellular carcinoma.

Merve Karayazili, Ulgen Celtik, Eda Ataseven, Deniz Nart, Orkan Ergun

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric surgery international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Merve KarayaziliDepartment of Pediatric Surgery, Faculty of Medicine, Ege University, Izmir, Turkey.
Ulgen Celtik *Department of Pediatric Surgery, Faculty of Medicine, Ege University, Izmir, Turkey.
Eda Ataseven *Department of Pediatric Oncology, Faculty of Medicine, Ege University, Izmir, Turkey.
Deniz Nart *Department of Pathology, Faculty of Medicine, Ege University, Izmir, Turkey.
Orkan ErgunDepartment of Pediatric Surgery, Faculty of Medicine, Ege University, Izmir, Turkey. orkanergun@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHepatocellular carcinoma (HCC), the second most common pediatric malignant liver tumor after hepatoblastoma, represents 1% of all pediatric tumors.

methodsA retrospective study was conducted on children with HCC treated at our center from March 2002 to October 2022, excluding those with inadequate follow-up or records. Demographic data, initial complaints, alpha-fetoprotein (AFP) values, underlying disease, size and histopathological features of the masses, chemotherapy, and long-term outcomes were analyzed.

resultsFifteen patients (8 boys, 7 girls) with a mean age of 11.4 ± 4.1 years (0.8-16.4 years) were analyzed. The majority presented with abdominal pain, with a median AFP of 3.9 ng/mL. Hepatitis B cirrhosis in one patient (6.6%) and metabolic disease (tyrosinemia type 1) in two patients (13.3%) were the underlying diseases. Histopathological diagnoses were fibrolamellar HCC (n:8; 53.3%), HCC (n:6; 40%). Four of the 15 patients underwent liver transplantation, and 9 underwent surgical resection. Due to late diagnosis, two patients were considered inoperable (13.3%). The survival rate for the four patients who underwent liver transplantation was found to be 75%.

conclusionSurgical treatment of various variants of HCC can be safely performed in experienced centers with a multidisciplinary approach, and outcomes are better than in adults.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationAdolescentChildChild, PreschoolFemaleFollow-Up StudiesHepatectomyHumansInfantMaleRetrospective StudiesSurvival RateTreatment OutcomeChildFibrolamellar HCCLiver resectionLiver transplantationPediatric hepatocellular carcinoma (HCC)Pediatric liver tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.